)
Glenmark Pharmaceuticals today opened a new manufacturing facility in Switzerland for supply of clinical trial material.
Glenmark Pharmaceuticals S.A (GPSA), a wholly-owned subsidiary of the company has opened its new GMP compliant monoclonal antibody manufacturing facility in La Chaux-de- Fonds, Switzerland, Glenmark Pharma said in a statement.
"This manufacturing facility supplements Glenmark's existing in-house discovery and development capabilities and will supply material for clinical development," it added.
Glenmark Pharma Biologics-President Michael Buschle said: "We have been doing cutting edge work in the area of novel monoclonal antibodies and have several monoclonal antibody candidates & bispecific antibodies in the pipeline. The manufacturing facility would help us bring these antibodies to the clinic faster..."
An antibody is a protein produced by plasma cells that is used by the body's immune system to identify and neutralise foreign particles such as bacteria and viruses.
The focus for the biologics R&D centre is to develop novel biologic entities for the treatment of pa
in, oncologic, inflammatory and respiratory conditions, Glenmark Pharma said.
Since its inception around 10 years back, Glenmark's biologics research centre has filed several patents on novel biologic entities, it added.
"GBR 500, its most advanced candidate has been licensed to Sanofi and is currently in Phase II development. GBR 900, a first-in-class molecule for treatment of chronic pain is currently in Phase I and GBR 830, an anti OX-40 antagonist, is scheduled to enter the clinic later this year," it said.
The Glenmark Pharma scrip was trading at Rs 539.90, down 0.03 per cent, on the BSE in the afternoon.
